Passage Bio, Inc. Share Price & Technical Analysis
PASG · $5.22 (+1.16%)
Healthcare / Biotechnology
$5.22
+1.16%
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PB…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, 4% avg return in past 3 year May month.
-65% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | -21% | -9% | -35% | 2% | – | – | – | – | – | – | – | -65% |
| 25 | -15% | -10% | -32% | -6% | 32% | -7% | -19% | 13% | 13% | -5% | 14% | 37% | 15% |
| 24 | 0% | 76% | -18% | -5% | -11% | -26% | 10% | -22% | -8% | -15% | 82% | -50% | 13% |
| 23 | 1% | -15% | -21% | 4% | -10% | -1% | -5% | -15% | -16% | -2% | -3% | 55% | -28% |
| 22 | -21% | -35% | -8% | -37% | -6% | 32% | -21% | 9% | -38% | -5% | -1% | 11% | -120% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$15.41M
P/E ratio
—
52W high
$20.00
52W low
$3.94
Volume
10,975
Beta
1.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Passage Bio, Inc. share price today?
- Passage Bio, Inc. (PASG) last traded around $5.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PASG have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PASG. Download the app for real-time alerts.
- How can I analyze Passage Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.